Hosted content

This page gives healthcare professionals access to resources developed by professional bodies or pharmaceutical companies. Items may contain pharmaceutical promotional information.

GSK logo

COPD: LAMA/LABA as initial maintenance therapy for appropriate symptomatic patients

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200014 V2.0

GSK logo

COPD: LAMA/LABA therapy—Real life case studies

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200015 V2.0

GSK logo

Why you might want to review patients with COPD receiving a LAMA

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200013

GSK logo

COPD: Have you done enough to implement guidelines?

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200012

GSK logo

Why use LAMA/LABAs as initial maintenance therapy in specific COPD patients?

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200011

GSK logo

LAMA/LABAs as initial maintenance therapy in COPD

Content funded and provided by GSK

This promotional resource has been funded and provided by GSK. Information intended for UK healthcare professionals only.
PM-GB-UCV-WCNT-200010

Management of opioid-induced constipation

The role of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the management of opioid-induced constipation (OIC)

Commissioned by Sandoz Limited

This educational reference document has been initiated, commissioned, and developed by Sandoz Ltd. Information intended for UK healthcare professionals only. 
View prescribing information

UK/MKT/RZM/20-0029f October 2020

Fostair Logo

Fostair (beclometasone/formoterol): key messages

Commissioned by Chiesi Ltd

This promotional resource has been commissioned and developed by Chiesi Limited. Information intended for UK healthcare professionals only.
Click here for Prescribing Information and Adverse Event Reporting.

UK-NEX-2000037 November 2020